Regenxbio (RGNX) executive compensation, 2026 proxy

Curran Simpson, President and Chief Executive Officer, was paid $4.2M in 2025, down 12% from $4.8M the year before.

Filed
April 14, 2026
Annual meeting
May 29, 2026
Pay year
2025
Named executives
3
CEO total pay
$4.2M-12% vs prior year
CEO pay in equity
74%$3.1M in awards
CEO Base Salary
$665,510Approved for fiscal 2025
CEO Target Cash Incentive
60%Percentage of base salary
Corporate Achievement
97%For annual cash incentives

How Simpson was paid

$4.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary16%Stock awards19%Option awards56%Non-equity incentive9%All other compensation0%

Named executive officers

ExecutiveTotal
Curran SimpsonPresident and Chief Executive Officer$4,200,712
Stephen Pakola, M.D.EVP, Chief Medical Officer$1,799,546
Patrick J. ChristmasEVP, Chief Strategy and Legal Officer$2,041,511

What changed and why

  • $4.2MCurran Simpson received total compensation of $4,200,712 in 2025.
  • $200KPatrick J. Christmas received a special transaction-related cash performance bonus of $200,000.
  • 97%Annual cash incentive payouts were determined based on a corporate performance achievement level of 97%.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.